Retrospective study of the safety of caspofungin in immunocompromised pediatric patients

Pediatr Infect Dis J. 2003 Aug;22(8):747-9. doi: 10.1097/01.inf.0000078164.80233.14.
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Age Factors
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / adverse effects
  • Antifungal Agents / administration & dosage*
  • Antifungal Agents / adverse effects
  • Caspofungin
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Echinocandins
  • Female
  • Follow-Up Studies
  • Humans
  • Immunocompromised Host*
  • Infant
  • Lipopeptides
  • Male
  • Mycoses / drug therapy*
  • Mycoses / immunology*
  • Peptides*
  • Peptides, Cyclic*
  • Retrospective Studies
  • Risk Assessment
  • Sampling Studies
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides
  • Peptides, Cyclic
  • Caspofungin